Company intelligence / Profile preview

AceLink Therapeutics

Newark, California, United Statesacelinktherapeutics.com ↗

Ownership: Private
Employees: ~5
Development stage: Phase 2

Overview

AceLink's lead candidate AL01211 has shown promising interim Phase 2 results in treatment-naïve classic male Fabry disease patients. The drug was generally safe and well-tolerated, with a 30mg once daily dose reducing GL3 levels by 50%, while a 60mg dose showed faster and greater reduction. Preliminary data suggests AL01211 stabilizes Fabry disease symptoms including eGFR and proteinuria levels, with positive trends in pain reduction, quality of life, and global disease symptom assessment. Topline data from this Phase 2 trial is expected in Q3 2025.

Therapeutic areas: Rare DiseasesNeurologyNephrology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

AL01211

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on AceLink Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AceLink Therapeutics.

Explore the full profile